Source link : https://newshealth.biz/health-news/os-win-for-enzalutamide-in-prostate-cancer-at-high-risk-for-biochemical-recurrence/
(MedPage Today) — BERLIN — Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, according to results from… Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118023 Author : Publish date : 2025-10-19 19:55:00 Copyright for syndicated content belongs to the linked Source.
The post OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence first appeared on News Health.
—-
Author : News Health
Publish date : 2025-10-19 19:55:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8